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Abstract
Title: Examining Executive Dysfunction in Dementia: Vascular Etiology as a
Contributor to Greater Impairment
Author: Julianne Szemko, M.S.
Major Advisor: Anthony LoGalbo, Ph.D.
Objective: The present study examines executive functioning and overall
neuropsychological functioning within a memory disorder clinic population
with a specific focus on examining performance on the Modified Wisconsin
Card Sorting Test (M-WCST) among individuals with and without
cerebrovascular disease.
Method: This study utilized test data collected between 2018-2022 from the research
database at the Health First Memory Disorder Clinic (HFMDC) in Melbourne,
Florida. Participants were included if they completed a brief neuropsychological
evaluation (BNE) at the HFMDC with the M-WCST, Trail Making Test - Form B
(TMT-B), and Color/Word subtest of the Golden Stroop as part of their battery and
were given either a diagnosis of Alzheimer’s disease (AD), vascular dementia (VaD),
or mixed dementia (AD + VaD).
Results: Results of a one-way multivariate analysis of variance (MANOVA)
showed that M-WCST raw scores were not significantly different across
diagnostic groups. However, descriptive statistics suggested the predicted
hypothesized trend in which individuals with diagnoses of VaD and mixed
dementia (AD + VaD) appeared to perform worse on the M-WCST when
compared to those with AD. Another MANOVA was conducted and results
iii

suggested a statistically significant difference in TMT-B performance and
Color/Word performance between the dementia diagnoses. Specifically,
individuals with VaD and mixed dementia (AD + VaD) both performed
significantly worse on TMT-B when compared to those with AD. Additionally,
individuals with mixed dementia (AD + VaD) performed significantly worse on
Color/Word when compared to those diagnosed with AD. Lastly, correlation
analysis revealed M-WCST scores were significantly correlated with performance
on other executive functioning measures including TMT-B and Color/Word, thus
contributing to the construct validity of the M-WCST as a measure of executive
functioning.
Conclusion: M-WCST scores were not significantly different between diagnostic
groups perhaps due to the smaller sample size of VaD participants. However,
TMT-B performance and Color/Word performance among the VaD group and
mixed dementia (AD +VaD) group were found to be worse when compared to the
AD group; therefore, further assisting in the differential diagnosis among
individuals with and without cerebrovascular disease. Lastly, M-WCST scores
were significantly correlated with other executive functioning measures which
further contributes to developing the construct validity of the M-WCST as a
measure of executive functioning in a memory disorder clinic population.
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Chapter 1
Introduction
The United States population continues to age rapidly. Currently, there are
more than 54 million adults ages 65 and older living in the United States
representing 16% of the population or one in every seven Americans. The
proportion of older adults has increased 36% from 2009-2019 when compared to
the under-65 population which only increased 3% over these 10 years (US Census
Bureau, 2021). The population of older adults is expected to continue to grow over
the next several decades according to The United States Census Bureau (2021),
projecting this specific population to reach 94.7 million in 2060. With an
expanding aging population comes a number of factors that must be considered.
For example, there are many positive protective factors for quality of life
associated with increased longevity, including the opportunity to continue
engaging in hobbies or activities that the individual enjoys, maintain employment,
travel, spend time with family, and other activities that can increase and maintain
well-being. However, there are also negative factors such as increased risk of
disease, disability, and other detrimental cognitive factors including dementia. In
fact, one of the largest challenges associated with the rapidly growing aging
population is dementia (Irwin et al., 2018). The number of Americans living with
Alzheimer’s disease, the most common cause of dementia, is expected to double
from approximately 5.8 million to 13.8 million by 2050, less than 30 years from
now (Alzheimer’s Association, 2022).
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These factors clearly highlight the importance of developing a greater
understanding of the complexities involved in caring for and working with
individuals ages 65 and older. These statistics also shed light upon the fact that
psychologists will likely continue to encounter an increasing number of older
adults in clinical practice. Therefore, it is essential to be adequately trained and
prepared for working with this population and informed about geriatric
psychological and cognitive assessment. Specifically, it is imperative to be able to
assess for and differentiate between various mental health disorders and
neurodegenerative diseases as there are several other confounding factors as well
as overlapping symptoms that can make it difficult to distinguish between
including delirium, depression, anxiety, vitamin deficiencies, adjustment reactions,
side effects from medications, or a combination of these problems. Knowing how
to differentiate between these factors will allow for the best practice,
recommendations, medications, etc. to be offered to these individuals. Early and
accurate diagnosis is also significant in reducing the cost involved in caring for
individuals for dementia as well as providing early care. In fact, early and accurate
diagnosis can save up to 7.9 trillion dollars in medical and care costs (Lynch,
2018). Being able to recognize dementia in its early stages may help slow the
progression of the disease by allowing doctors and psychologists to provide earlier
interventions including prescribing medications, enacting behavioral and diet
changes, increased exercise, cognitive retraining techniques, etc.
Fortunately, the Diagnostic and Statistical Manual of Mental Disorders,
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fifth edition (DSM-5), includes specific criteria to assist in differentiating between
common mental health disorders and neurodegenerative disease processes that
affect the elderly (APA, 2013). By creating a set of guidelines to accurately
identify and diagnose cognitive decline, it provides an effective way to detect and
therefore manage the disease. The DSM-5 refers to cognitive decline in terms of
either a mild or major Neurocognitive Disorder (NCD). The NCD category in the
DSM-5 encompasses the group of disorders in which the primary deficit is in
cognitive function and this impaired cognition is acquired, not developmental.
Specifically, a mild NCD is characterized by “modest” cognitive decline in one or
more cognitive domains based on concern from the individual themselves/an
informant or documented through neuropsychological testing. Additionally, for a
mild NCD, the cognitive deficits seen in the individual do not interfere with their
ability to complete instrumental activities of daily living (IADL). IADLs often
consist of managing finances, managing medications, and driving. With a mild
NCD, the IADLs must remain “essentially” intact as compensatory strategies such
as setting reminders are able to be used (APA, 2013). Of note, activities of daily
living (ADLs) can be differentiated into basic ADLs (BADLs), which pertain to
aspects of self-care including bathing, dressing, and grooming, in addition to
instrumental ADLs, which typically refer to more complex tasks as mentioned
above.
The diagnosis of a major NCD goes one step further than minor NCD
requiring “significant” cognitive decline in one or more cognitive domains based
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on concern from the individual themselves, concern from an informant or
preferably documented through standardized neuropsychological testing.
Additionally, the cognitive deficits that are seen in the individual do interfere with
their ability to complete IADLs. Of note, the suspected etiology for either minor or
major cognitive decline can be specified using various subtypes in the DSM-5.
These specifiers include Alzheimer’s disease (AD), vascular dementia (VaD),
dementia with Lewy bodies, dementia due to Parkinson’s disease, frontotemporal
dementia, etc. (APA, 2013). Dementia is subsumed under the term major NCD in
the DSM-5. However, many of the dementias or neurodegenerative diseases can be
attributed to multiple etiologies and can be characterized as a comorbidity (e.g.,
mixed Alzheimer's disease-vascular pathology).
It is important to differentiate among the various suspected etiologies or
types of dementia in order to provide accurate and helpful coping strategies,
compensatory strategies, behavioral and environmental recommendations, medical
treatments, etc. As mentioned earlier, it is also important to delineate initial
symptoms and clinical presentations as precisely as possible in order to
differentiate between the different subtypes of dementia, as in later stages of the
progression of the disease many of the dementias tend to look similar due to fairly
global impairments (Howard, 2020). A useful way to differentiate among the
different types of dementias is by looking at patterns in the neuropsychological
testing during relatively earlier stages before unique elements of each disease
process dissolve and the condition overall progresses beyond recognition (Jacova
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et al., 2007). A comprehensive neuropsychological test battery that is used to
assess for dementia must include measures from each of the cognitive domains.
The cognitive domains form the basis on which the NCDs and their subtypes may
be diagnosed. In order to achieve a diagnosis of minor or major NCD, a decline or
impairment must exist in one or more neurocognitive domains, such as complex
attention, executive functioning, learning and memory, language, perceptualmotor, and social cognition (APA, 2013). The domain of complex attention
involves divided attention, sustained attention, selective attention and information
processing speed. The domain of executive functioning involves planning, decision
making, working memory, and mental flexibility. The domain of learning and
memory involves immediate memory, recent memory which includes cued recall
and recognition memory, and long-term memory. The domain of language
involves expressive language like naming and fluency, and receptive language.
The domain of perceptual-motor skills involves visual perception, handwriting,
copying, and manipulating items. Lastly, the domain of social cognition involves
recognition of emotions, behavioral regulation, theory of mind, and social
appropriateness (APA, 2013).
While the DSM-5 outlines basic criteria for both mild and major NCD,
additional criteria were developed to be more effective in differentiating between
specific dementia subtypes. For example, the National Institute on Aging funded
The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) in an
effort to standardize the neuropsychological measures that are used for the
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assessment and diagnosis of Alzheimer’s disease (AD; Fillenbam et al., 2008).
Researchers developed a standardized assessment battery that proved reliable and
valid for assessing AD as well as a standardized method of viewing the
neuroimaging markers for AD. Additionally, CERAD formed suitable training tools
to be used within all of the Alzheimer Disease treatment centers to further assist in
the accurate diagnosis of AD (Fillenbam et al., 2008). In a similar fashion, the
Neuroepidemiology Branch of the National Institute of Neurological Disorders and
Stroke (NINDS) convened an International Workshop with support from the
Association Internationale pour la Recherche et l'Enseignement en Neurosciences
(AIREN) in an effort to create reliable and valid research criteria for the diagnosis
of vascular dementia (VaD). They discussed the use of appropriate
neuropsychological assessments, brain imaging techniques, clinical features of
VaD, various subtypes of VaD, etc. as a guide for accurate diagnosis of VaD
(Roman et al., 1993).
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Chapter 2
Study Purpose
The purpose of this study is to gather information on how to differentiate
between AD and VaD, specifically in relation to the cognitive domain of executive
functioning. This is significant as executive functions typically decline in both AD
and VaD (D’Onofrio et al., 2018). Indeed, the fundamental purpose of the
proposed study is to gather data on executive functioning and overall
neuropsychological functioning from a memory disorder clinic population with a
specific focus on examining performance on an instrument that is commonly used
to measure executive functioning: the Modified Wisconsin Card Sorting Test (MWCST) among individuals with and without cerebrovascular disease. To further
illustrate the significance of the study, an explanation of necessary background
information pertaining to the importance of accurate assessment of executive
functioning within a memory disorder clinic population will be presented.
Specifically, the introduction will include: (1) the current understanding of what is
known about healthy aging; (2) a description of cognitive decline and the
development of dementia; (3) a description of Alzheimer’s disease; (4) a
description of vascular dementia; (5) a description of mixed dementia (AD +
VaD); (6) the current use of measurements used to assess executive functioning;
(7) information about the M-WCST, what aspects of executive functioning it
measures specifically, and its ability to differentiate between AD and VaD; and
finally, (8) the specific aims and hypotheses that will be addressed in this study.
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Chapter 3
Review of the Literature
Healthy Aging
One of the first steps in determining whether an individual has dementia is to
be able to distinguish the difference between very mild or subtle cognitive changes
seen in healthy normally aging adults compared to somewhat more substantial
cognitive changes that are indicative of abnormal aging or a neurodegenerative
disease process such as dementia. The neurocognitive changes observed in normal
aging have been well documented in the literature. For example, previous research
has shown that cognitive abilities like vocabulary are resistant to brain aging and
may even improve over time with age; however, other abilities including memory,
processing speed, and conceptual reasoning tend to decline gradually with age
(Harada et al., 2013).
These cognitive abilities can be characterized as belonging to either crystallized or
fluid intelligence. Crystallized and fluid intelligence are often used to describe patterns
that are seen in neurocognitive changes over the lifespan. Crystallized intelligence
increases with age as it is based upon prior learning and past experiences. Common
examples of crystalized abilities include general knowledge and vocabulary. Older adults
tend to perform better on tasks that require the use of crystallized intelligence when
compared to younger adults as this ability accumulates over time. In contrast, fluid
intelligence refers to an individual’s innate ability to reason, think flexibly, process and
learn new information, solve problems, and attend to their environment (Harada et al.,
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2013). The cognitive domains that are considered to use fluid intelligence include
executive functioning, processing speed, memory, and psychomotor ability. These fluid
cognitive abilities typically peak around 30 years-old and then decline at an approximate
rate of -0.02 standard deviations per year as they continue to age (Salthouse, 2012).
Therefore, these fluid abilities and the cognitive domains that they represent constitute the
normal cognitive changes and declines that are observed in normal aging.
Of note, many of the normal, age-related cognitive changes that are observed
in healthy older adults are the result of slowed processing speed which can have
implications across a variety of cognitive domains (Harada et al., 2013). Healthy
older adults have shown to perform worse on tasks of complex attention including
selective and divided attention due to slower processing abilities (Salthouse et al.,
1995 as cited in Harada et al., 2013). In regard to the domain of memory, normal agerelated changes also appear to be related to slowed processing speed (Luszcz &
Bryan, 1999 as cited in Harada et al., 2013). There are two types of memory,
declarative (explicit) and non-declarative (implicit), that reveal different changes
across the lifespan. Declarative memory is considered a conscious recollection of
facts and events (e.g., knowledge of the first president of the United States) while
non-declarative memory operates automatically and accumulates information that is
not accessible to conscious recollection (e.g., knowing how to ride a bike or tie a
shoe). Declarative memory can also be broken down into two subtypes: semantic and
episodic memory. Semantic memory involves fund of information, language usage,
and practical knowledge (e.g., knowing that the sky is blue). Episodic memory deals
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with personally-experienced events which is why it is also referred to as
autobiographical memory (e.g., remembering your first day of school; Harada et al.,
2013). Of note, episodic memory loss is typically the first sign of abnormal aging
(Craik, 2008). Episodic memory has been found to remain relatively steady until 60
years of age. If there is a significant decline in this form of memory before the age of
60, this indicates abnormal or pathological aging (Irwin et al., 2018). Unlike
declarative memory and its subtypes, non-declarative memory tends to remain
unchanged as an individual ages (Harada et al., 2013).
The domain of executive functioning also shows a normal age-related decline
due to its fluid nature in which older adults tend to think more concretely as they
age. However, significant impairment in executive functioning ability that is seen
before the age of 65 indicates an abnormal age-related change in cognition (Irwin et
al., 2018). Additionally, executive abilities that require a speed or motor component
are particularly susceptible to age effects in which older adults tend to perform
worse due to slower processing speed abilities (Harada et al., 2013). Similarly,
spatial ability also declines with age in which studies have found that older adults
take longer to perform tasks that require an understanding of spatial information
(Irwin et al., 2018). This is also a direct consequence of the decreased processing
speed ability that occurs with normal aging. Meanwhile, the domain of language
tends to remain relatively intact and stable with increasing age (Harada et al., 2013).
Verbal fluency is the exception to this in which healthy older adults have been
shown to perform worse over time on measures that involve the spontaneous
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generation of words within a certain category (e.g., letters, animals, vegetables) in a
certain amount of time, typically 60 seconds. This is also likely due to a decline in
processing speed (Harada et al., 2013).
The structure of the brain also experiences significant changes as an
individual ages. There are both normal structural and functional brain changes that
occur with age, in addition to abnormal changes. For example, the grey matter of the
brain begins to naturally reduce in volume after the age of 20 (Harada et al., 2013).
Additionally, age-related changes also occur in the temporal lobes where healthy
adults have shown decreases in the volume of the hippocampus (Raz et al., 2004).
However, extensive decrease of the hippocampus including hippocampal sclerosis or
extreme atrophy is not a part of normal aging and often indicative of Alzheimer’s
disease (Braak & Braak, 1996). Similarly, the entorhinal cortex has been shown to
undergo early decreases in volume in Alzheimer’s disease, but not in normal aging
(Braak & Braak, 1996). White matter volume decreases are also common with
normal aging and constitute a much greater change in volume loss when compared
to grey matter changes (Harada et al., 2013). White matter changes that are seen in
areas such as the corpus callosum or superior longitudinal fasciculus, however, are
not seen in normal aging and may be indicative of pathology (Irwin et al., 2018).
Other normal brain changes seen with increasing age include reduced total brain
weight, ventricular and sulcal expansion, loss of myelination, and thinning of
cerebral vasculature (Lindenberger, 2014).
Lastly, it is important to consider that normal age-related cognitive changes
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do not impair an individual’s ability to perform everyday activities. If these
cognitive changes do prevent the individual from carrying out functional tasks, it is
no longer considered healthy or normal aging but rather indicative of more
substantial cognitive decline. Apparent decreases in cognitive functioning that are
actually attributable to biological losses of the sensory systems such as hearing, or
vision are commonly seen in normal aging. However, decreases in cognitive
functioning that are not due to an environmental or natural biological cause but
rather an underlying neurodegenerative disease process are not seen in normal aging
(Sánchez-Izquierdo & Fernández-Ballesteros, 2021).
Cognitive Decline and Dementia
The development of dementia is often thought of in terms of meeting or
surpassing various thresholds. Indeed, different stages of cognitive ability and decline
exist with age. As stated above, some individuals experience mild and normal agerelated cognitive changes that do not negatively impact functioning. Other individuals,
however, might experience a mild but measurable decline in cognitive ability,
characterized as mild cognitive impairment (MCI; Petersen et al., 1997). The criteria for
MCI as defined by Petersen et al. (1997) is based on subjective cognitive complaints or
decline, objective cognitive impairment (typically 1-2 standard deviations below prior
functioning) measured using neuropsychological testing, relative preservation of ADLs,
and the absence of dementia.
In fact, there are several MCI subtypes that an individual may be diagnosed
with, and depending on the subtype, this may increase the individual’s chances for
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progression to dementia (Bradfield, 2021). The MCI subtypes include single or multiple
domain amnestic MCI and single or multiple domain non-amnestic MCI. The terms
“single” or “multiple” refer to the number of cognitive domains that are deemed
impaired using neuropsychological testing. The terms “amnestic” or “non-amnestic”
refer to whether or not the domain of memory in particular is impaired (Bradfield,
2021). Research has shown that there is a 10 to 15% conversion rate from MCI to AD
per year (Tábuas-Pereira et al., 2016). Of note, it is important to maintain that not all
individuals diagnosed with MCI will progress to a dementia. Some individuals with
MCI remain stable or convert back to normal (Koepsell & Monsell, 2012). However,
80% of individuals with the amnestic subtype of MCI have been observed to progress to
AD within 6 years of follow-up (Tábuas-Pereira et al., 2016).
In clinical practice, it is sometimes difficult to recognize when a patient who
presents with memory complaints has an underlying neurodegenerative disease process
that is going to progress to a dementia (Ross & Bowen, 2002). As there is no singular
diagnostic test that is used to diagnose dementia, the healthcare provider must rely on
accurate history from the patient and a reliable historian as well as other assessments
such as neuropsychological testing or brain imaging. Additionally, it is important to note
that there are certain factors that can put an individual at increased risk for developing
dementia, as well as factors that can be considered protective against dementia. Age is
the strongest risk factor for cognitive decline and developing dementia (WHO, 2021).
Cardiovascular factors such as uncontrolled diabetes, hypertension, history of previous
strokes, tobacco use, etc. have also been found as risk factors for cognitive decline
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(Chen et al., 2009). Other risk factors include obesity, substantial alcohol consumption,
lower educational levels, increased drug use, and gender with more women being found
to have certain dementias like AD or VaD (Chen et al., 2009).
There are also certain genes that may serve as risk factors for dementia
including the apolipoprotein E(ApoE) gene. Specifically, the ApoE e4 allele has been
found to be a major risk factor for developing Alzheimer’s disease in all ethnic groups
for men and women between 40 and 90 years (Farrer, 1997 as cited in Chen et al.,
2009). On the other hand, the presence of the ApoE e2 allele appears to function as a
protective factor against cognitive decline. Other protective factors include a high
education level, moderate alcohol consumption, regular physical activity, and a healthy
diet (Chen et al., 2009).
As mentioned earlier, dementia can be categorized into several subtypes
depending on the underlying causes/etiologies. Dementia is therefore often referred to or
considered a broad umbrella term for a set of symptoms in which an individual
experiences memory loss, confusion, personality, behavior changes, etc. as a result of a
group of illnesses that affect the brain and cause a progressive decline in functioning.
Alzheimer’s disease (AD) accounts for about 60-80% of individuals with dementia,
followed by vascular dementia (VaD; 20–25%), mixed dementia (5–10%), Parkinson’s
disease, dementia with Lewy bodies, physical brain injury, Huntington’s disease,
Creutzfeldt-Jacob disease, frontotemporal dementia, and lastly, normal pressure
hydrocephalus (Chen et al., 2009).
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Alzheimer’s Disease
The term Alzheimer’s disease was first coined in 1906 when Dr. Alois
Alzheimer was investigating the case of his patient, Auguste Deter, in the
Frankfurt Psychiatric Hospital. Per reports by Auguste’s husband, beginning in
1901, Mr. Deter had noticed several changes in Auguste’s behavior and
functioning leading up to her death. He noticed a fast progression and increasing
intensity of symptoms including memory loss, paranoia, aggressiveness,
hallucinations, and progressive confusion and disorientation (Hippius &
Neundörfer, 2003). Dr. Alzheimer observed and noted the changes in Auguste’s
functioning from 1901 at the time of her admission to the hospital, to 1906 at the
time of her death at the age of 55. Upon autopsy, Dr. Alzheimer was able to
investigate her brain where he stated that he had identified “an unusual disease of
the cerebral cortex.” He found that her cerebral cortex was “thinner” than normal,
and he also discovered the presence of beta-amyloid plaques and neurofibrillary
tangles, which we now know to be the neuropathological hallmarks of
Alzheimer’s disease (Hippius & Neundörfer, 2003).
As a result of Dr. Alzheimer and his discovery, research has been able to
focus on identifying how, why, and when an individual presents with symptoms of
Alzheimer’s disease. As previously mentioned, AD is not a normal part of aging,
despite the greatest risk factor for developing AD being increasing age. In fact,
there are two types of AD that are differentiated depending on what age an
individual begins to develop symptoms. Both of these types of AD have a genetic
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component that play a role in whether or not an individual may develop the
disease. The first type is early-onset AD which typically affects individuals
younger than age 65 and the second is late-onset AD which affects individuals
ages 65 and older (Seltzer & Sherwin, 1983). The early-onset subtype of AD is
rare, representing less than 10% of all people with AD and typically presenting
when an individual is in their 40’s or 50’s (Felson, 2020). Late-onset AD is more
common, but both types have an insidious onset with accompanying gradually
progressive cognitive decline. Additionally, there is a familial form of AD known
as familial Alzheimer’s disease (FAD) which is the rarest subtype of AD making
up only 1% of cases (Felson, 2020). This form of AD has a strong genetic factor
in which the disease is inherited unlike the typical late-onset AD which is not
inheritable in nature.
As previously mentioned with the case of Auguste Deter, all types of AD
are able to be confirmed via autopsy. This is because at autopsy, the presence of
the neuropathological hallmarks of AD which include the plaques and tangles, can
be confirmed (Braak & Braak, 1996). Plaques are comprised of the protein, betaamyloid, which build up and abnormally accumulate and clump together. Tangles
are comprised of the protein, tau, which collect inside neurons and become
intertwined (Braak & Braak, 1996). Unfortunately, these plaques and tangles are
unable to be seen with common imaging measures such as computerized
tomography (CT) scans or magnetic resonance imaging (MRI) scans. However, it
is useful to be able to identify the presence of specifically the beta-amyloid
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plaques in the brain as the deposition of these plaques have been found to precede
cognitive symptoms in AD (Rodrigue et al., 2009). Therefore, the collection and
deposition of plaques are considered a preclinical marker of disease. In fact, it
takes approximately 15 years to develop cognitive and behavioral symptoms after
the amyloid collects in the brain (Selkoe & Hardy, 2016). In 2002, researchers
developed a type of amyloid imaging agent that was able bind to the plaques in the
brain using a positron emission tomography (PET) scan which they called CPittsburgh Compound B (PiB; Marcus et al., 2014). This imaging agent as well as
another, called Amyvid, is used in PET scans to be able to detect amyloid plaque
accumulation (Jack et al., 2013). A positive amyloid PET scan can therefore help
to determine whether there is beta-amyloid in the brain to help increase the
clinical certainty of diagnosis before having to wait until autopsy (Jack et al.,
2013).
While MRI and CT scans are unable to detect amyloid deposits, they can
be used to identify other imaging markers of AD. AD is typically considered a
cortical dementia which means that it involves the grey matter of the brain and
regions such as the temporal and parietal lobes (Salmon & Filoteo, 2007).
Specifically, MRI and CT scans are able to show the affected areas of the brain
and various regions of grey matter loss in the hippocampus, entorhinal cortex,
medial temporal lobes, and lateral frontal lobes. Therefore, the presence of parietal
atrophy, enlarged temporal horns, enlarged Sylvian fissures suggestive of
temporal lobe atrophy, and hippocampal atrophy all are imaging markers of AD
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pathology (Frisoni et al., 2010).
In addition to using imaging techniques to identify AD,
neuropsychological testing is also used to confirm a diagnosis of AD. This is
because a structural abnormality that is seen on a brain imaging scan is not always
indicative of impaired functioning in that specific region of the brain.
Neuropsychological assessments are thereby designed to identify the extent and
severity of an individual’s cognitive and behavioral impairments. As mentioned
earlier, common symptoms of AD include increased memory loss and confusion,
word finding difficulties, misplacing items, poor judgement, and changes in mood
including increased paranoia, delusions, hallucinations, etc. (López & DeKosky,
2008). Neuropsychological tests are able to detect changes in regard to how the
individual is functioning in certain cognitive domains including learning and
memory, language, attention, processing speed, executive functioning,
visuospatial skills, adaptive functioning, mood, etc. The neuropsychological
profile of AD is characterized by impairment in memory with loss of information
over time, difficulty with recall, recognition, and learning, language difficulties
pertaining to object naming, a discrepancy between phonemic and semantic
fluency ability often called a phonemic-semantic split, and occasional deficits in
executive functioning and selective attention (Weintraub et al., 2012).
Accurate descriptions of how individuals are functioning in day-to-day activities
and their ability to carry out IADLs is also a significant factor when determining
the presence of AD or any form of dementia. Impairments in IADLs are
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significant and necessary for the diagnosis of AD (McKhann et al., 1984).
Information regarding daily functioning should be obtained from knowledgeable
family members or friends if the primary report is coming from the person who
may be exhibiting the decline in cognition and functioning. This is because selfreport may not always be accurate in individuals who are experiencing cognitive
impairment due to loss of insight (Frank et al., 2011). Additionally, reports of
IADLs and daily functioning ability can be supported by neuropsychological test
findings using standardized adaptive functioning measures to solidify accuracy of
diagnosis (e.g., the Texas Functional Living Scale developed by Cullum et al.,
2001).
While there is currently no cure for AD, two classes of drugs are often
used in the management of symptoms (Mehta et al., 2012). These medications
include acetylcholinesterase (AChE) inhibitors like galantamine, rivastigmine, and
donepezil as well as the N-methyl-D-aspartate (NMDA) antagonist, memantine.
Donepezil, rivastigmine and galantamine all prevent an enzyme called
acetylcholinesterase from breaking down the neurotransmitter, acetylcholine,
which promotes memory formation and consolidation (Mehta et al., 2012).
Glutamate, another neurotransmitter, tends to be produced in abundance in AD
and can lead to synaptic damage. Therefore, NMDA antagonists like memantine
are useful in regulating the overproduced glutamate. However, side effects of
these medications can include dizziness, headaches, gastrointestinal problems, and
confusion (Mehta et al., 2012).
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Vascular Dementia
Vascular dementia is defined as a decline in cognitive functioning that
impacts the ability to carry out IADLs, resulting from ischemic or hemorrhagic
cerebrovascular disease (CVD) or from cardiovascular or circulatory disturbances
that have injured brain regions involving memory, cognition, and behavior (Paul
et al., 2005). As previously mentioned, the DSM-V criteria provide good
sensitivity but low specificity in the diagnosis of VaD, but the NINDS-AIREN
criteria are the most specific of all available criteria and are used most commonly
in research (Roman et al., 1993). The NINDS-AIREN criteria suggest that the
diagnosis of VaD cannot be made without radiological evidence of
cerebrovascular disease (CVD; Roman et al., 1993). Specifically, VaD can be
attributed to multiple infarcts (large vessel disease) or small vessel disease. Large
vessel disease would include ischemic or hemorrhagic legions from repeated
cerebrovascular accidents (CVAs) or strokes. These include large territorial or
strategic infarcts (Staekenborg et al., 2008). Small vessel disease is used to
describe lacunar infarcts which are smaller infarcts located in the deeper white
matter of the brain. These are smaller white matter changes or bilateral thalamic
lesions (Staekenborg et al., 2008). Multi-infarct VaD is thereby slightly different
in presentation when compared to small vessel disease VaD. Multi-infarct VaD
has a sudden onset, results in a step-wise progression (cognitive functioning
remains stable for a period and then declines after experiencing a stroke), and the
impairments that an individual experiences depends on the location of the infarcts
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(Paul et al., 2005). Small vessel disease on the other hand has an insidious onset,
gradual progression, and results in impairments in executive functioning, verbal
fluency, and psychomotor slowing (deficits in attention and processing speed),
while memory is often relatively preserved (Paul et al., 2005). The presence of
vascular lesions in the brain has not always been associated with cognitive decline
(Paul et al., 2005). That is why it is imperative that in the diagnosis of VaD, the
cognitive deficits must be related to vascular changes or cerebrovascular events in
the brain. If the presence of CVD, lacunes, CVAs, or white matter disease is not
what is causing the cognitive decline, then it is not considered a vascular dementia
and another etiology should be considered.
Determining whether VaD is the appropriate diagnosis involves
confirming vascular damage as the dominant pathology that accounts for the
cognitive deficits supported with neuropsychological test results, reports from an
informant regarding IADLs, and neuroimaging evidence of CVD. The
neuropsychological profile for VaD is dependent on the area affected with regards
to whether it is abrupt and due to multiple strokes (multi-infarct), or slower in
progression and insidious (small vessel disease). Typically, a decline in frontalexecutive function (e.g., impairments in abstract reasoning, planning, mental
flexibility) and complex attention (including processing speed) is what is observed
among individuals with VaD (Venkat et al., 2015). Meanwhile, memory is
relatively intact and typically not a major concern for VaD, unlike AD where the
primary complaint is memory loss. Therefore, individuals with VaD are more
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likely to present with symptoms of slowed thinking, periods of confusion, reduced
ability to organize thoughts or actions, decline in ability to develop a plan and
execute that plan, unsteady gait, and depression or apathy (Venkat et al., 2015). In
fact, depression, apathy, irritability, and poor initiative are common complaints in
those with VaD (Alzheimer’s Association, 2022).
The prevalence of VaD is more common in men, which is in direct contrast
with AD which is more common in women (Akhter et al., 2021). Research has
shown that men are more likely to have significant cardiovascular risk factors
when compared to women. In fact, in the United States, men have a greater risk of
having a heart attack and are twice more likely to have a heart attack than women
(Maas & Appelman, 2010). Additionally, men in the United States smoke slightly
more than women and use more tobacco products, another significant
cardiovascular risk factor (Pampel, 2006). Furthermore, VaD has been shown to
be more prevalent in populations that are affected by cerebral small vessel disease
such as African Americans, Asians, and Hispanic populations (Vijayan & Reddy,
2016). Additionally, VaD can occur at any age but the prevalence increases
significantly after age the age of 65 (Hébert & Brayne,1995).
VaD is often considered a subcortical dementia meaning it affects blood
vessels throughout the brain including within subcortical white matter, which
contributes to neuronal dysfunction in these areas and ultimately causes related
cognitive impairment (Salmon & Filoteo, 2007). It involves the slowing of
cognition and motor function due to deficits in executive functioning in addition
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to altered gait, speech, affect, and mood (Paul et al., 2005). This is also in direct
contrast to the previously mentioned cortical dementia, AD, which manifests with
early and severe memory disturbances, aphasia, agnosia, and apraxia resulting
from lesions typically seen in the posterior cortical association regions (Paul et al.,
2005).
The major risk factors for VaD are the same as those for heart disease,
stroke, or CVD. The risk factors include hypertension, high cholesterol levels,
diabetes, smoking, obesity, previous history of strokes, other risk factors for
atherosclerosis and arteriolosclerosis, atrial fibrillation, and other conditions
increasing the risk of cerebral emboli traveling through the blood stream
(McVeigh & Passmore, 2006). Controlling these factors may help to lower the
chances of developing VaD or from having another vascular change that would
lead to increased impairments in cognition. Therefore, the major treatment or
prevention measures for VaD include changing lifestyle factors such as increasing
daily exercise, abstaining from smoking, and managing cardiovascular risk factors
like diabetes, cholesterol levels, and blood pressure (McVeigh & Passmore, 2006).
Additionally, medications that are often prescribed to help slow the progression
down of VaD are the same medications that are prescribed for AD as well, as
mentioned earlier (Battle et al., 2021). Specifically, a meta-analysis conducted by
Battle et al. (2021) found that the AChE inhibitors, donepezil and galantamine,
have a beneficial effect on cognition in people with VaD.
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Mixed Dementia (AD + VaD)
Mixed dementia occurs when an individual has more than one type of
dementia, meaning that the cognitive decline that is seen within the individual is
attributed to multiple etiologies. In other words, the abnormalities that are
characteristic of more than one type of dementia are happening simultaneously in
the brain in a mixed dementia. The most common form of mixed dementia occurs
when the abnormal protein deposits associated with AD (e.g., plaques and tangles)
coexist with sufficient cerebrovascular abnormalities thought to be contributing to
cognitive impairments and linked to VaD (e.g., CVD, lacunes, white matter
disease; Custodio et al., 2017). This form of mixed dementia (AD + VaD) is a
very common pathological finding seen in older adults with a prevalence of about
of 22% (Custodio et al., 2017). The term “mixed dementia” from this point on will
be specifically referring to the form of mixed dementia including AD and VaD
unless other specified.
Mixed dementia symptoms tend to vary as this depends on the types of
brain changes involved and the brain regions affected. In several cases, symptoms
tend to be similar to or even indistinguishable from those of AD such that there
are complaints of memory loss in addition to a general slowness and confusion
that is seen with VaD. Diagnosis once again depends on cognitive deficits
supported with neuropsychological test results, decline in IADLs, and
neuroimaging evidence of vascular changes. The neuropsychological profile of
mixed dementia is therefore a combination of that seen with AD and VaD
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including a decline in memory, executive functioning, attention, and processing
speed (Kang et al., 2016). Clinically, the typical neuropsychological profile of AD
combined with neuroimaging to support the diagnosis of a vascular component
playing a role is often what leads to a diagnosis of mixed dementia. Treatment and
prevention is also a combination of what is suggested for AD and VaD including
medication (AChE inhibitors or NMDA antagonists) as well as managing vascular
risk factors, exercising, and maintaining a healthy diet.
There are studies showing that the cognitive performance of patients with
mixed dementia is lower than that observed in patients with AD, particularly in
the attention, memory, executive functioning, and visuospatial domains (Custodio
et al., 2017). Dong et al. (2013) analyzed the cognitive profiles of mild to
moderate mixed dementia and AD and found that when compared to those with
AD, individuals diagnosed with mixed dementia demonstrated greater
impairments in global cognitive composite function, attention, and visual
construction tasks. Additionally, Reed et al. (2007) found that individuals
diagnosed with AD performed poorly in memory with only 10% of cases showing
impairments in executive functioning; however, individuals with mixed dementia
demonstrated greater deficits in specifically executive functioning compared to
those with solely AD. Similarly, Kang et al. (2016) also found significant
differences in frontal/executive functioning between individuals with mixed
dementia and AD, in that those diagnosed with mixed dementia had greater
impairments in executive functioning compared to those with AD. Individuals
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with mixed dementia and AD did not differ significantly in any of the other
domains Kang et al. (2016) analyzed including attention, language, memory, and
visuospatial functioning. Additionally, data from imaging and clinicalneuropathological correlation studies have suggested that the presence of vascular
pathology compounds the clinical presentation of AD and thus increases both the
risk and severity of cognitive impairment (Ezzati et al., 2017). Therefore, it
appears that the vascular component of mixed dementia serves to exacerbate the
presentation and symptoms of AD and lead to an even further decline in an
individual’s cognitive functioning. More importantly, it appears that executive
dysfunction is highly common among individuals diagnosed with mixed dementia
(Kang et al., 2016; Reed et al., 2007).
Neuropsychological Measures for Executive Functioning
As mentioned earlier, executive functioning is one of several important
cognitive domains that should be assessed during a dementia evaluation.
Executive functioning can be defined as higher level thought processes that
involve things such as complex attention, multitasking, problem-solving, and
decision making. Research has shown that executive functions can be broken
down into six domains: mental flexibility, working memory, planning, inhibitory
control, verbal fluency, and processing speed (Faria et al., 2015). Mental
flexibility refers to the ability to switch between mental tasks and changing
strategies within the same task. Working memory refers to the temporary storage
and management of information for a short period of time. Planning is comprised
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of the ability to mentally anticipate the correct way to carry out a task or reach a
certain goal. Inhibitory control refers to the ability to control impulsive responses
and use reasoning. Verbal fluency is comprised of the ability to form a strategy for
word searching. Lastly, processing speed is the time that it takes to process
information in a set task.
Executive dysfunction can be measured objectively through the use of
specific neuropsychological tests. There is a multitude of executive functioning
tests that are available; however, these tests vary according to the specific domains
of executive functioning that are to be assessed. Because a wide range of
executive functioning measures exist, it is crucial to identify which specific
measures are most useful for assessing executive dysfunction in the context of a
dementia evaluation. Of the aforementioned domains of executive functioning,
Faria et al. (2015) found that mental flexibility, verbal fluency, planning, working
memory, and inhibitory control are the most studied and used in
neuropsychological evaluations. Meanwhile, according to Faria et al. (2015),
processing speed was more frequently examined in a separate domain referred to
as attention. Seven tests of executive functioning were utilized in more than 20%
of the articles on aging research reviewed by Faria et al. (2015), including the
Trail Making Test (TMT) Form B; Verbal Fluency Test (VFT) - F, A and S; VFT Animals category; Clock Drawing Test (CDT); Digit Span Forward and Backward
subtests of the Weschler Adult Intelligence Scale-Revised (WAIS-R); Stroop Test;
and the Wisconsin Card Sorting Test (WCST) and its variations.
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The Trail Making Test (TMT), specifically Form B, is a task of set shifting
and mental flexibility that requires an individual to alternate between numbers and
letters in consecutive order (Brown & Partington, 1942). The individual is
instructed to draw a line between 24 circles that are randomly arranged on a page
including both numbers and letters. They are instructed to begin at number 1 and
draw a line from a number to a letter as fast as they can. The TMT-B is scored
based upon how long it takes the individual to complete the test. It includes
numbers from 1-13 and letters from A-L. It is a task of mental flexibility as the
individual must switch between numbers and letters and remember to do this or it
could result in a set-loss error (they do not maintain switching between numbers
and letters) or a sequencing error (they perform the wrong sequence of order e.g.,
1-B). The TMT was originally developed by Brown & Partington (1942) and is
now part of numerous assessment batteries (e.g., Delis, Kaplan, & Kramer, 2001).
The Verbal Fluency Test (VFT) is a test of verbal functioning consisting of
two tasks: category fluency (semantic fluency) and letter fluency (phonemic
fluency; Spreen & Benton, 1977). The VFT- F, A, S is a letter fluency task which
entails having the individual name as many words as they can think of beginning
with these 3 letters in 60 seconds for each trial. However, certain rules must be
followed, such as not using proper nouns (names of people or places) or the same
stem of a word with different endings (e.g., love, loving, lover). The score is then
calculated by adding the total number of correct words they were able to name for
each letter. The VFT – Animals category refers to category fluency in which the
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individual is asked to name as many animals as they can think of within 60
seconds. There are no restrictions on the first letter of the animals that are named,
and it is scored by totaling the number of correct animals they were able to name
within a minute. These two tests are a task of verbal fluency as the individual must
form a mental strategy for searching for the various words. The VFT was
originally developed by Spreen and Benton (1977) and also has been modified and
used in multiple assessment batteries.
The Clock Drawing Test (CDT) measures an individual’s ability to plan as
they are required to draw a clock, place all the numbers within the clock, and set
the hands to a specific time (Freedman et al., 1994). It is a test of planning as the
individual must plan how to space the numbers correctly, ensure the numbers are
not rotated, ensure they are not placed in counterclockwise order, etc. The Digit
Span Forward and Backwards subtests of the WAIS-R measure working memory
as the individual is instructed to repeat the numbers said by the examiner in the
same order for Digit Span Forward and repeat the same numbers in reverse order
in Digit Span Backward (Wechsler, 1981). Both subtests become progressively
more difficult adding an additional number to recall per item. The subtest is
discontinued if the individual receives a score of 0 on both trials of an item. These
subtests are considered to tap into the domain of working memory as the
individual must temporarily store, remember, and manipulate the numbers that are
read to them in their mind. The Digit Span subtests are part of the larger
intelligence scale created by Wechsler (1955).
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The Stroop Test measures the executive domain of inhibitory control and
is comprised of three conditions (Golden, 1978). The first condition, word
reading, involves having an individual read as many words as they can in 45
seconds. The second condition, color naming, involves having the individual name
the colors of the ink that the letter “X” is printed in in 45 seconds. Lastly, the final
condition which primarily measures inhibitory control involves an individual
naming the color of the ink that the words “red, blue, and green” are written in.
The individual must inhibit the brain’s natural response to read the word “red” and
instead state the color of the ink that this word is printed in. For example, the word
“red” might be printed in blue ink so the correct answer would be to say “blue.”
There are several versions of this test that have been developed and refined also
within assessment batteries by Delis and Kaplan (2001).
Lastly, the Wisconsin Card Sorting Test (WCST) measures problem
solving and mental flexibility (Grant & Berg, 1948). This test consists of 128
cards that must be sorted according to one of three categories – color (red, blue,
green, or yellow), form (crosses, circles, triangles, or stars), or number (one, two,
three, four) – based upon the 4 stimulus cards that are presented. The
categorization rules change after 10 consecutive response cards have been sorted
correctly. The individual is told that they must figure out how to sort the cards
correctly but is not told how to sort them. After making a choice and placing a
response card under a stimulus card, they are only instructed whether placement of
the card is right or wrong. Therefore, the individual must use their ability to

30

problem solve, test hypotheses, and ultimately shift the rules accordingly and sort
the cards by the new rule. The WCST was originally published by Grant and Berg
(1948) and now has undergone several revisions and modifications with the most
used modified version being the Modified Wisconsin Card Sorting Test (MWCST) created by Nelson (1976). The M-WCST has only 48 cards thus
increasing the motivation for the individual to complete the task, increasing their
understanding of the test through decreasing the number of total cards, and
decreasing the frustration, potential mental fatigue, and overall time taken to
complete the test in comparison to the original version. Additionally, the MWCST has been shown to possess substantially better psychometric properties
than would be expected from previously published studies of the original WCST
(Kopp et al., 2019). Specifically, Kopp et al. (2019) found that the split-half
reliability of the Executive Function Composite in the M-WCST (the number of
categories correct and perseverative errors combined) equals .95, within 95%
credibility limits between .922 and .972. They concluded that the reliability of the
M-WCST is satisfactory and the M-WCST is therefore a legitimate and reliable
neuropsychological tool for the assessment of executive function (Kopp et al.,
2019). The modified version of the WCST, the M-WCST (Schretlen, 2010), is the
primary neuropsychological assessment that will be examined in the present study.
Schretlen’s (2010) M-WCST is a standardized version of Nelson’s (1976)
Modified Card Sorting Test.
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Modified Wisconsin Card Sorting Test Findings
The purpose of measuring problem solving and mental flexibility within
the overarching domain of executive functioning is of particular interest within the
neuropsychological field, and within the realm of conducting dementia
evaluations specifically. Research has shown that individuals with a vascular
component to their cognitive decline, or more specifically a vascular dementia
(VaD), tend to perform worse on these measures when compared to individuals
with Alzheimer’s disease (AD; Reed et al., 2007; Kang et al., 2016). For example,
Oguro et al. (2006) differentiated between AD and VaD using the Frontal
Assessment Battery (FAB). While this is not the same type of test as the WCST or
the M-WCST, the FAB assesses executive functions related to the frontal lobe
including mental flexibility, conceptualization, motor programming, sensitivity to
interference, inhibitory control, and environmental autonomy (Dubois et al.,
2000). Oguro et. al (2006) found that specifically the mental flexibility subtest of
the FAB, which is a verbal fluency measure, was the only subtest that significantly
discriminated VaD from AD and healthy controls. This study provides support
that frontal executive functions are more impaired in VaD than in AD and that
mental flexibility in particular is a significant component which contributes to that
difference (Oguro et al., 2006). Since the M-WCST is a test of mental flexibility
within the overarching domain of executive functioning, this research could
therefore be replicated and expanded upon using the M-WCST.
Additionally, Desmond (2004) also concluded in his review of the
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literature that individuals who are diagnosed with VaD exhibit significantly more
perseverations and perseverative errors when compared to patients with AD,
particularly during tasks that tap into frontal lobe or executive functions. He found
that patients with VaD exhibit greater deficits in tasks that measure planning,
speed of mental processing, verbal fluency, and mental flexibility (Desmond,
2004). This research also provides support for the potential of utilizing the MWCST to differentiate between the diagnoses of VaD and AD as it reveals that
individuals with VaD tend to have more perseverative errors when compared to
those with AD and the M-WCST incorporates a total number of perseverative
errors an individual makes. Of note, perseverative errors occur when an individual
continues to provide the same response despite being informed about a switch in
rules or directions. This type of error is related to executive dysfunction as it is
regarded as a failure to inhibit a prepotent response, or a dominant response
(Sullivan et al., 1993).
Overall, there is a great deal of research on the original 128-card version of
the WCST as well as research on several of the other tests that measure mental
flexibility and executive functioning. However, less research exists on the MWCST, in part because it is a relatively newer version of the test. However,
further establishing the clinical utility of the M-WCST is of significant importance
as using the modified version in the assessment of dementia could allow for a
decrease in overall time of administration, decrease in patient frustration, decrease
in early discontinuation, and an increase in overall understanding. As mentioned
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earlier, Kopp et al. (2019) found that the M-WCST, using 48 cards, was
sufficiently reliable in the clinical assessment of neurological patients. They
further went on to state that using even 24 cards might render satisfactory
reliability. Using Spearman–Brown Split-Half Reliability Coefficients (rSB) for MWCST Scores, their results suggested that the sampling-based split-half reliability
of the Executive Function Composite was rSB = .927 when it was estimated solely
from the initial 24 cards. This was within 95% credibility limits between rSB =
.865 and rSB = .969. Their finding indicates that the Executive Function Composite
appears to possess good split-half reliability (rSB ≥ .700), even when taken from a
considerably abbreviated test (Kopp et al., 2019).
Furthermore, Sánchez et al. (2017) studied the utility of the WCST-64 in
patients with sporadic late onset AD. Vayalakkara (2000) developed the WCST64, another modified version of the WCST-128, which utilizes only 64 cards. The
WCST-64 has the same administration rules as the original WCST-128 but only
utilizes the first 64 cards, whereas the M-WCST has a slightly different
administration procedure. Their results suggest equivalence between using the full
128-card version and the 64-card version with individuals diagnosed with late
onset AD thus providing support that a modified version can be used to determine
diagnosis with the same results. Sánchez et al. (2017) came to this conclusion after
comparing performance on the WCST-128 to the WCST-64 in terms of the
different variables of interest (perseverative errors, non-perseverative errors, etc.).
Su et al. (2008) also evaluated the construct validity of the WCST-64 in
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individuals who had a stroke and found that the WCST-64 was best represented by
a three-dimensional model comprising response inflexibility (factor 1), ineffective
hypothesis-testing strategy (factor 2), and set maintenance (factor 3). While this
research did not look at specific variables of interest within the WCST (e.g.,
number of categories correct, number of perseverative errors), but instead overall
factors, it did support the use of the WCST-64 in stroke patients with cognitive
impairment. The researchers also went on to say, “despite the fact that executive
dysfunction is the most prominent cognitive deficit reported in patients with
vascular cognitive impairment, data on the validity of the WCST in discriminating
stroke patients with varying severity levels of cognitive impairment are still
lacking” (Su et al., 2008, p. 275). This validates and provides additional support
that this is a much-needed area of research as not many studies have been
conducted using the even shorter version of the WCST, the M-WCST with 48
cards.
Lastly, a study by Chao et al. (2013) specifically utilized the M-WCST
with 48 cards and compared its utility when diagnosing individuals with AD and
VaD, which is very similar to the proposed present study. They compared those
with AD, those with VaD, and normal cognition by analyzing the differences
among M-WCST scores. The researchers classified the results of the M-WCST
into five groups for analysis: number of categories completed, preservative error
score, non-preservative error score, unique error, and total error. They found that
the number of categories completed, unique errors, and total errors can
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differentiate individuals with AD, VaD, and healthy controls from each other
(Chao et al., 2013). Specifically, they found a significant difference between the
control group, individuals with AD, and individuals with VaD in these three
variables due to the greater declination of executive function in AD and VaD
patients. Those with VaD completed the least number of categories and had the
most total errors compared to those with AD and healthy individuals (Chao et al.,
2013). This study was performed in Taiwan with a small number of participants
(32 AD individuals, 18 VaD individuals, and 38 healthy controls). It is therefore
proposed that this study be replicated and expanded upon within a memory
disorder clinic population in order to better understand the differences in executive
functioning and mental flexibility in those with AD compared to VaD and become
better able to differentiate between these diagnoses in a shorter amount of time.

36

Chapter 4
Rationale and Significance of Current Study
As noted earlier, knowing which type of dementia an individual has can
help when predicting how the dementia might progress, developing accurate
behavioral and environmental recommendations, and understanding how to best
manage the symptoms. Therefore, specifically being able to differentiate between
AD and VaD, or being able to identify whether there is a vascular component to
the suspected etiology of a dementia, is important from a therapeutic and
prognostic point of view. Research has shown that VaD is associated with greater
healthcare costs, higher rates of comorbidity, reliance on caregivers, need for
institutionalization, and 50% lower median survival (3–4 years compared to 6–7
years) when compared to AD (Levine & Langa, 2011). The results from the
current study might help with differential diagnosis in that people with vascular
impairment are more likely to perform worse on the M-WCST (as seen in Chao et
al., 2013). Additionally, from a functional neuroanatomical standpoint, greater
executive deficits would be expected in someone with cerebrovascular
abnormalities, particularly in frontal/subcortical regions (Sudo et al., 2017). This
is in comparison to AD, which in its earlier stages, is less likely to involve the
frontal lobes (Frisoni et al., 2010). Therefore, observing greater M-WCST
impairment among individuals with VaD would perhaps lend support to this
notion of greater frontal/subcortical involvement in VaD compared to AD.
Furthermore, the benefits of conducting this study also include future use
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and support of the M-WCST in neuropsychological assessment batteries. This is
particularly important as the other versions of the WCST require up to
approximately 60 minutes to administer and are typically difficult for patients with
dementia who find it to be a demoralizing and degrading experience and may
reject or discontinue the test. It is much harder for elderly individuals to finish the
full WCST; hence, if the task is discontinued prematurely, the results are not able
to be used. The M-WCST is much shorter and allows for a faster administration,
less patient fatigue, less frustration, and thus a greater chance of utilizing the
results.
Objectives and Hypotheses
Objective #1: Determine whether there are differences in M-WCST scores
across diagnostic groups (e.g., AD, VaD, and mixed [AD+VaD] dementia).
Hypothesis #1: Individuals with VaD and mixed dementia (AD + VaD)
will perform worse on the M-WCST in terms of demonstrating fewer categories
correct, greater perseverative errors, and greater total number of errors than
individuals with AD.
Objective #2: Expand upon the research finding that individuals with a
vascular component to their cognitive disorder demonstrate greater executive
dysfunction compared to individuals diagnosed with AD.
Hypothesis #2: It is hypothesized that individuals with VaD and mixed
dementia (AD + VaD) will perform worse on other executive functioning
measures including exhibiting lower scores on both TMT-B and the Color/Word
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subtest of the Golden Stroop when compared to individuals with AD.
Objective #3: Contribute to the construct validity of the M-WCST as a
measure of executive functioning within a memory disorder clinic population.
Hypothesis #3: M-WCST scores will significantly correlate to scores on
other executive functioning measures including TMT-B and the Color/Word
subtest of the Golden Stroop independent of diagnosis.

39

Chapter 5
Method and Procedures
Data Collection
This study utilized test data collected between January 2018 through August
2022 from the research database at the Health First Memory Disorder Clinic
(HFMDC) in Melbourne, Florida. Participants were included if they were aged 65
and older and were referred to or presented to the HFMDC due to memory
concerns. The HFMDC is a not-for-profit agency funded primarily through the
Alzheimer’s disease Initiative of the State of Florida Department of Elder Affairs
for the purpose of providing services for individuals in the community who are
concerned about Alzheimer’s disease or other memory-related disorders. Specific
inclusion criteria for this study involved patients who completed a brief
neuropsychological evaluation (BNE) at the HFMDC with the M-WCST, TMT-B,
and Color/Word subtest as part of their battery and were given either a diagnosis of
AD, VaD, or mixed dementia (AD + VaD).
An a priori power analysis was conducted using G*Power version 3.1.9.7
(Faul et al., 2007) to determine the minimum sample size required to test the
current study’s hypotheses. Results indicated the required sample size to achieve
80% power for detecting a large effect, at a significance criterion of α = .05, was N
= 48 for a one-way multivariate analysis of variance (MANOVA). This means each
diagnostic group (AD, VaD, and mixed dementia) should have a total of 16
participants.
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Measures
Participants were administered the BNE by a Florida Tech student
psychometrist at the HFMDC. The researcher of the present study, also a student
psychometrist, assisted with data collection through administering BNEs weekly.
The BNE assesses a variety of cognitive domains including learning and memory,
language, attention and processing speed, executive functioning, visuospatial skills,
and basic adaptive functioning skills. The BNE also assesses aspects of emotional
and psychological functioning. The following tests were administered to
participants: Supraspan Serial List Learning Task; Brief Visual Memory Test,
Revised (BVMT-R); Digit Span subtest of the Wechsler Adult Intelligence Scale,
4th Edition (WAIS-IV); Clock Drawing Task; Trail Making Test (TMT) A & B;
Golden Stroop Test (Stroop); Modified Wisconsin Card Sorting Test (M-WCST);
Controlled Oral Word Association Task (COWAT), phonemic and semantic; Mack
SF4; Comprehension and Repetition subtests of the Western Aphasia Battery
(WAB); Narrative Writing Sample of the Boston Diagnostic Aphasia Examination
(BDAE); Texas Functional Living Scale (TFLS); Geriatric Anxiety Inventory
(GAI); Geriatric Depression Scale (GDS); Patient Health Questionnaire-9 (PHQ-9).
Modified Wisconsin Card Sorting Test (M-WCST; Schretlen, 2010).
The M-WCST is a modification of the original Wisconsin Card Sorting Test
(WCST) that results in 48-cards rather than the original 128-card deck. The MWCST eliminates all cards from the original WCST that share more than one
attribute with a stimulus card. Simply put, each response card whose stimuli
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matched a stimulus card in both color and form was therefore eliminated. This led
to the 48-card deck in the M-WCST which is used along with four stimulus/key
cards. This and other modifications that were made allow for cognitively impaired
older adults to understand the directions more easily. Therefore, the M-WCST
assesses perseveration, abstract reasoning, and mental flexibility resulting in less
patient frustration. The individual is prompted by the examiner to sort the response
cards under the four key cards according to certain rules. However, the purpose of
the test is to have the individual decide where to put the response cards and they
will be prompted with either a “yes” or “no” from the examiner regarding their
decision. Six consecutive correct responses are required and can either be sorted by
color, form, or number. The individual must repeat the same order (e.g.
C,F,N,C,F,N) to receive 6/6 correct categories. Four scores are calculated for the
M-WCST: Number of Categories Correct, Number of Perseverative Errors,
Number of Total Errors and Percent of Perseverative Errors. Additionally, an
Executive Function Composite score can also be calculated. The test generally
takes about 15 to 20 minutes to administer and 5 minutes to score. The normative
sample population age ranges from 18-90 years. The M-WCST has also been
shown to have excellent sensitivity to impaired problem solving and perseverative
reasoning in individuals with neurological conditions including neurodegenerative
diseases such as dementia.
Trail Making Test - Form B (TMT-B; Brown & Partington, 1942). The
Trail Making Test - Form B is considered an executive functioning measure as it is
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a task of set shifting and mental flexibility (Brown & Partington, 1942). The task
requires an individual to alternate between numbers and letters in consecutive order
by drawing a line between 24 circles that are randomly arranged on a page. The
TMT-B is scored based upon how many seconds it takes the individual to complete
the test and takes into consideration the individual’s age and education level. Also,
if the individual takes more than 300 seconds to complete TMT-B, they are
instructed to discontinue the test. Even if the individual discontinues the test before
300 seconds due to confusion or fatigue, they automatically receive a raw score of
300 seconds according to the scoring guidelines.
Golden Stroop subtest Color/Word (Stroop; Golden, 1978). The Stroop
Test measures the executive domain of inhibitory control and is comprised of three
conditions (Golden, 1978). The first two conditions, word reading and color
naming, are often used as measures of attention and processing speed. The final
condition, color/word, measures inhibitory control and therefore exclusively taps
into executive functioning. It involves an individual naming the color of the ink that
the words “red, “blue,” and “green” are written in while inhibiting the natural
response to read the word rather than state the color of the ink it is printed in. This
test is scored utilizing scaled scores based upon age and the number of correct
answers they produce in 45 seconds.
Procedures
Both archival and prospective data was used in this study (data from 20182022). Individuals who presented to the HFMDC for memory concerns underwent
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a formal clinical interview with either the geriatrician or nurse practitioner and a
licensed clinical social worker to gather historical information regarding the onset
of memory problems, functional abilities, psychological functioning, etc. At that
time, patients were also administered a brief cognitive screening measure, the
Montreal Cognitive Assessment (MoCA). If it was decided that the patient
undergo neuropsychological testing, they were scheduled for a BNE to inform
treatment and determine a diagnosis so that recommendations could be made. The
BNE was administered by a trained Florida Tech student psychometrist in the
clinical psychology doctoral program under the supervision of board-certified
licensed clinical neuropsychologist. A senior psychometrist then checked the
scoring and administration of each BNE for accuracy. Additionally, test
administration and scoring procedures for the neuropsychological tests included in
the BNE are standardized to ensure accuracy and eliminate subjectivity. Informed
consent was obtained by all patients on the day of testing in which they give
permission for their de-identified test data to be used for research purposes.
Following their consent to continue, the BNE test battery was administered to
assess the patient’s cognitive functioning. Total testing time took approximately 2
to 2 ½ hours to complete.
Following the completion of the BNE testing, each individual patient case
was reviewed by a multi-disciplinary team comprised of geriatrician, social
worker, neuropsychologist, neurologist, as well as pharmacy and clinical
psychology doctoral students. Diagnostic impressions and recommendations were
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made based on the information obtained during the clinical interview as well as
based upon a review of the neuropsychological test data findings and brain
imaging. Each patient was thereby diagnosed using the Tenth Revision of the
International Classification of Diseases and Related Health Problems (ICD-10;
WHO, 2016) diagnostic criteria. Individuals who met the diagnostic criteria for
Alzheimer’s disease, vascular dementia, and mixed dementia (AD+VaD) were
included in this study. Specifically, all participants underwent the full BNE test
battery including the full completion of the M-WCST, TMT-B, and Color/Word
subtests and received one of the specific diagnoses mentioned before being
included in this study. If the individual discontinued TMT-B, they automatically
received a raw score of 300 seconds according to the scoring guidelines. However,
if an individual discontinued the M-WCST or the Color/Word subtest, their data
was not included in this study as the scoring guidelines do not provide information
on discontinuation for the M-WCST or Color/Word.
Research Design and Analysis of Data
The researcher of the present study was granted permission by the Health
First Memory Disorder Clinic to utilize their research database. Approval from the
Florida Institute of Technology Institutional Review Board (IRB) was obtained
prior to analyzing data. Informed consent was also obtained prior to each
participant completing their BNE.
Data analyses were performed using the Statistical Package for the Social
Sciences (SPSS) – Version 28. Descriptive statistics were obtained to include
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means, standard deviations, and frequencies for patient demographic variables.
Specifically, for Hypotheses #1, a one-way MANOVA was conducted to
determine how individuals with the diagnoses of AD, VaD, and mixed dementia
(AD + VaD) perform on the M-WCST, utilizing raw scores. For Hypothesis #2, a
one-way MANOVA was also performed to compare the raw scores obtained on
other executive functioning tests (TMT-B and Color/Word subtest of the Golden
Stroop) among those with VaD and mixed dementia (AD + VaD) compared to
those with AD. Lastly, for Hypothesis #3, a Spearman’s correlation was used to
determine if there is a significant relationship between M-WCST raw scores and
raw scores on other executive functioning measures including TMT-B and the
Color/Word subtest of the Golden Stroop independent of diagnosis.
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Chapter 6
Results
Participants
An overall total of 268 patients met the inclusion criteria and were
therefore included in the current study. Among them, 198 patients were diagnosed
with AD (average age was 80.19, SD = 6.11, 65.2% female), 19 patients were
diagnosed with VaD (average age was 82.74, SD = 5.91, 63.2% female), and 51
patients were diagnosed with mixed dementia (AD + VaD; average age was 82.16,
SD = 5.75, 58.8% female). A one-way ANOVA was conducted to determine if the
mean age was significantly different between diagnostic groups as this could
impact the overall results. There was homogeneity of variances, as assessed by
Levene's test for equality of variances (p = .910), and results suggested the group
means were not statistically significant, p > .05.
Among the 268 participants, the average education level was 13.56 (SD
=2.37). In regards to race, a majority of the total participants self-identified as
being Caucasian/White (89.2%), followed by African American (7.8%), Asian
(1.9%), and Native American (0.4%), while 0.7% of individuals provided no
response. Additionally, in regards to ethnicity, a majority of the total participants
self-identified as non-Hispanic (95.1%) while 4.1% of individuals self-identified
as Hispanic, and 0.8% of individuals provided no response. For more information
pertaining to descriptive statistics of patient demographic information see Table 1.
It is of note to mention that the results of the a priori power analysis
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suggested that each diagnostic group (AD, VaD, and mixed dementia) should have
a total of 16 participants. Thus, the obtained sample size of N = 198 for AD, N =
19 for VaD, and N = 51 for mixed dementia appears to be adequate to test the
study hypotheses.
Statistical Analyses
A one-way MANOVA was conducted to determine the effect of dementia
diagnosis on M-WCST performance. Three variables of M-WCST performance
were assessed: number of categories completed, total number of errors, and
number of perseverative errors. The three dementia diagnoses were AD, VaD and
mixed (AD+VaD). Dementia diagnosis served as the independent variable with
three levels (e.g., AD, VaD, and mixed dementia) while number of categories
completed, total number of errors, and number of perseverative errors on the MWCST served as the three dependent variables. Preliminary assumption checking
revealed that data was not normally distributed, as assessed by Shapiro-Wilk test
(p < .05). However, there were no univariate outliers in the data, as assessed by
inspection of a boxplot for values greater than 3.0 box-lengths from the edge of
the box. There was homogeneity of variance-covariances matrices, as assessed by
Box's M test of equality of covariance matrices (p = .114). Respectively; there
were linear relationships, as assessed by scatterplot, and no multicollinearity as
assessed by Pearson correlation (number of categories completed and total number
of errors, r = -.808, p < .001; total number of errors and perseverative errors, r =
.788, p < .001; perseverative errors and number of categories completed, r = -
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.550, p < .001). Therefore, the only assumption that was violated was the data
being not normally distributed. The decision was thereby made to conduct the
MANOVA as non-normality has been found to not affect Type 1 error rate
sustainability (Maxwell & Delaney, 2004; Blanca et al., 2017).
Initial descriptive statistics suggested that individuals with diagnoses of
VaD (M = 2.05, SD = 1.08) and mixed dementia (AD + VaD; M = 1.92, SD =
1.21) completed fewer categories on the M-WCST when compared to those with
AD (M = 2.34, SD = 1.44). Individuals with VaD (M = 26.53, SD = 8.04) and
mixed dementia (AD + VaD; M = 28.75, SD = 8.99) also appeared to have a
greater number of total errors on the M-WCST when compared to those with AD
(M = 25.30, SD = 8.67). And lastly, those with VaD (M = 13.00, SD = 8.65) and
mixed dementia (AD + VaD; M = 15.49, SD = 10.48) appeared to have a greater
number of perseverative errors on the M-WCST when compared to those with AD
(M = 12.00, SD = 8.65).
However, and more importantly, results of the one-way MANOVA
indicated the differences among the dementia diagnoses on the combined MWCST variables were not statistically significant, F(6, 526) = 1.239, p = .285;
Wilks' Λ = .972; partial η2 = .014. While the descriptive statistics visually show
the predicted trend of Hypothesis 1 (see Figure 1), the one-way MANOVA did not
find statistically significant differences between dementia diagnoses and MWCST performance, thus rejecting Hypothesis 1.
A second one-way MANOVA was conducted to determine the effect of
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dementia diagnosis (AD, VaD, mixed AD + VaD) on TMT-B and Color/Word
performance. Preliminary assumption checking revealed that there were no
univariate outliers in the data, as assessed by inspection of a boxplot for values
greater than 3.0 box-lengths from the edge of the box. The data was not normally
distributed, as assessed by Shapiro-Wilk test (p < .05). However, there was no
multicollinearity as assessed by Pearson correlation (r = -.378, p < .001). There
was homogeneity of variance-covariances matrices, as assessed by Box's M test of
equality of covariance matrices (p = .006). A scatterplot also revealed that there
were linear relationships, respectively. Again, the only assumption that was
violated was the data being not normally distributed. The decision was made to
conduct the MANOVA as non-normality does not affect Type 1 error rate
sustainability as the F-test used in a MANOVA is considered robust to deviations
from normality (Maxwell & Delaney, 2004; Blanca et al., 2017).
Initial descriptive statistics suggested that individuals with VaD (M =
277.59, SD = 52.22) and mixed dementia (AD + VaD; M = 265.45, SD = 57.20)
appeared to have taken longer to complete TMT-B than those with AD (M =
231.69, SD = 76.45). Additionally, preliminary descriptive statistics suggested that
individuals diagnosed with VaD (M = 11.82, SD = 7.07) and mixed dementia (AD
+ VaD; M = 11.65, SD = 6.63) appeared to have performed worse on Color/Word
than those with AD (M = 15.56, SD = 9.01).
Results of the one-way MANOVA confirmed there was a statistically
significant difference among the dementia diagnoses on the combined dependent
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variables, F(4, 524) = 4.434, p = .002; Wilks' Λ = .936; partial η2 = .033. Followup univariate ANOVAs were therefore conducted to show exactly where these
differences lie, and results showed that there was a statistically significant
difference in TMT-B performance among the dementia diagnoses, F(2, 263) =
6.816, p = .001; partial η2 = .049. Additionally, there was a statistically significant
difference in Color/Word performance among the dementia diagnoses, F(2, 263) =
5.233, p = .006; partial η2 = .038. A Bonferroni correction was made so that
acceptance of statistical significance for the univariate ANOVAs is set at p < .025
rather than p < .05 because there are two dependent variables. Tukey post-hoc
tests showed that there was an increase in the time it took individuals to complete
TMT-B from the AD group to the VaD group with a mean increase of 45.90, 95%
CI [3.09, 88.72], which was statistically significant (p = .032). Additionally, there
was an increase in the time it took individuals to complete TMT-B from the AD
group to the mixed dementia (AD + VaD) group with a mean increase of 33.76,
95% CI [7.16, 60.37], which was statistically significant (p = .009). This confirms
what was seen in the initial descriptive statistics differences, that individuals with
VaD (M = 277.59, SD = 52.22) and mixed dementia (AD + VaD; M = 265.45, SD
= 57.20) significantly took longer to complete TMT-B than those with AD (M =
231.69, SD = 76.45). With regards to Color/Word performance, Tukey post-hoc
tests showed that there was a statistically significant decrease in performance from
the AD group to the mixed dementia (AD + VaD) group with a mean decrease of
3.91, 95% CI [0.76, 7.05], p = .01. This also confirms what was seen in the initial
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descriptive statistics, that individuals diagnosed with mixed dementia (AD + VaD;
M = 11.65, SD = 6.63) performed significantly worse on Color/Word than those
with AD (M = 15.56, SD = 9.01). These results support Hypothesis 2.
Lastly, a Pearson correlation was attempted to assess the relationship
between M-WCST raw scores and raw scores on other executive functioning
measures (TMT-B and Color/Word). Preliminary analyses showed no outliers,
however, not all variables were normally distributed, as assessed by ShapiroWilk's test (p < .05). Spearman's rank-order correlation was therefore conducted
because this test has been found to be robust to deviations from normality
(Sheskin, 2011). Additionally, Spearman’s rank order correlation was determined
to be the better statistical analysis, as each variable revealed monotonic
relationships rather than linear relationships.
Multiple Spearman's rank-order correlations were conducted to assess the
relationship between M-WCST raw scores (number of categories completed, total
number of errors, number of perseverative errors) and raw scores on other
executive functioning measures (TMT-B and Color/Word). Preliminary analysis
revealed monotonic relationships, as assessed by visual inspection of a scatterplot.
There were several statistically significant correlations that provide support
for Hypothesis 3. There was a medium negative correlation between number of
categories completed on the M-WCST and TMT-B performance, indicating that
the number of categories completed on the M-WCST decreases as time taken to
complete TMT-B increases, rs = -.334, p < .001. There was also a small positive
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correlation between number of categories completed on the M-WCST and
Color/Word performance, indicating that the number of categories completed on
the M-WCST increases as performance on Color/Word increases, rs = .272, p <
.001. Meanwhile, there was a medium positive correlation between total number
of errors on the M-WCST and TMT-B performance, indicating that the total
number of errors on the M-WCST increases as time taken to complete TMT-B
increases, rs = .325, p < .001. There was also a small negative correlation between
total number of errors on the M-WCST and Color/Word performance, indicating
that the total number of errors on the M-WCST increases as Color/Word
performance decreases, rs = - .294, p < .001. Lastly, there was a medium positive
correlation between number of perseverative errors on the M-WCST and TMT-B
performance, indicating that the number of perseverative errors on the M-WCST
increases as time taken to complete TMT-B increases, rs = .310, p < .001.
Additionally, there was a small negative correlation between number of
perseverative errors on the M-WCST and Color/Word performance, indicating
that the number of perseverative errors on the M-WCST increases as Color/Word
performance decreases, rs = - .286, p < .001. See Table 2 for more information.
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Chapter 7
Discussion
Impact of Study
As previously suggested, it is important to differentiate among the various
suspected etiologies or types of dementia in order to provide accurate and helpful
coping and compensatory strategies, behavioral and environmental
recommendations, as well as the most up to date medical treatments for patients.
Specifically being able to differentiate between AD and VaD, or being able to
identify whether there is a vascular component to the suspected etiology of a
dementia, is also important from a therapeutic and prognostic point of view.
Differentiating between AD and VaD often involves the examination of the
cognitive domain of executive functioning, in addition to neuroimaging review.
The current study focused on the M-WCST as well as TMT-B and the Color/Word
subtest of the Golden Stroop, three neuropsychological measures of executive
functioning.
The current results suggested that individuals with diagnoses of VaD and
mixed dementia did not perform significantly worse on the M-WCST when
compared to those with AD, thus rejecting Hypothesis 1. However, descriptive
statistics did visually show the predicted trend of performance noted in Hypothesis
1 (see Figure 1). While this finding lacks statistical significance, it does prove
somewhat promising for future research as the means showed differences in MWCST across diagnostic groups in the hypothesized trend. Perhaps this finding
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could be statistically significant in future studies that include a larger number of
VaD participants. With an increase in VaD participants, future studies may be able
to better determine the utility of the M-WCST in detecting whether there is a
cerebrovascular component to a dementia.
Furthermore, another trend was seen in the current results that warrants
further discussion. Results suggested that individuals with mixed dementia (AD
+VaD) performed worse than any other diagnosis (e.g., individuals with pure VaD
or pure AD). This was seen in the preliminary descriptive statistics conducted for
Hypothesis 1 where individuals with mixed dementia (AD + VaD) appeared to
have lower scores on the different variables of the M-WCST based upon means
and standard deviations. Additionally, the significant results of the one-way
MANOVA that was run for Hypothesis 2 showed this trend as well where
individuals with mixed dementia (AD + VaD) had lower scores and/or performed
worse on TMT-B and Color/Word than those with pure VaD or pure AD with
regards to means and standard deviations, respectively. In simpler terms, the trend
that was seen suggested that individuals with AD performed the best on the
executive functioning measures (M-WCST, TMT-B, and Color/Word) followed
by those with pure VaD, and lastly those with mixed dementia (AD + VaD). An
individual with mixed pathology therefore might have worse cognitive impairment
than either diagnosis alone. Interestingly, there is research that supports this trend
of poor performance in individuals with mixed dementia (AD + VaD). Data from
imaging and clinical-neuropathological correlation studies have suggested that the
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vascular component of mixed dementia exacerbates the presentation and
symptoms of AD and lead to an even further decline in an individual’s cognitive
functioning (Ezzati et al., 2017). Therefore, it makes sense that individuals with
mixed dementia (AD + VaD) may have performed the worst out of the three
diagnostic groups tested in the present study.
As indicated above, current results did reveal statistically significant
differences in performance on TMT-B and the Color/Word subtest of the Golden
Stroop among diagnostic groups, supporting Hypothesis 2. Individuals with VaD
and mixed dementia (AD + VaD) performed significantly worse on TMT-B when
compared to those with AD. Additionally, results showed that individuals with
mixed dementia (AD + VaD) performed significantly worse on the Color/Word
subtest when compared to those diagnosed with AD. These particular results help
to further expand upon the research finding that individuals with a vascular
component to their cognitive disorder demonstrate greater executive dysfunction
than those with AD.
It is worth exploring why TMT-B and Color/Word were found to be more
sensitive to detecting differences among the three diagnoses in this study while the
M-WCST was not. One explanation for this finding might be in regards to how
each of these tests measure executive functioning. For example, both TMT-B and
Color/Word are time-based measures where the longer it takes an individual to
complete these tests, the worse their overall score is. The M-WCST is not a timebased measure as individuals can take as long as they need to complete the test,
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and this will not positively or negatively impact their performance / score in any
way. Therefore, while individuals with VaD or a vascular component to their
cognitive disorder (mixed AD + VaD) show deficits in executive functioning, they
also tend to have significant deficits in processing speed (Venkat et al., 2015).
This means that perhaps the differences in performance between the three
diagnoses on TMT-B and Color/Word were more easily detected than the MWCST due to the aspect of timing which allows for additional deficits in
processing speed to be revealed.
Lastly, variables assessing performance on the M-WCST were found to be
significantly correlated to performance on other executive functioning measures
including TMT-B and the Color/Word subtest of the Golden Stroop independent
of dementia diagnosis. This finding supports Hypothesis 3 and contributes to
developing the construct validity of the M-WCST as a measure of executive
functioning in a memory disorder clinic population. This is an important finding
as further establishing the clinical utility of the M-WCST as a measure of
executive functioning in the assessment of dementia could allow for a decrease in
overall time of administration, decrease in patient frustration, decrease in early
discontinuation, and an increase in overall understanding of the patient.
Additionally, executive functioning is of particular concern in this population as
executive dysfunction causes significant problems for older adults with regards to
their functional ability. For example, deficits in executive functioning have been
shown to lead to difficulties with planning and paying attention to details when

57

managing medications or finances which could be especially detrimental for older
adults who may have more complex medications or be prone to financial
scamming (Marshall et al., 2011). Executive dysfunction has also been found to
lead to difficulties with older adults’ ability to reason and make appropriate
decisions while driving (Martyr, 2012). Therefore, proving support for the use of
the M-WCST as another valid measure of executive functioning is beneficial for
the future of neuropsychology and neuropsychological assessment as well as for
the overall functioning of this population.
Limitations and Areas for Future Research
One of the most prominent limitations of this study was the small sample
size of the VaD group compared to the other diagnostic groups. One reason for
this may be in part due to the location of where participants were gathered, a
memory disorder clinic. As mentioned earlier, memory loss is not a primary
presenting symptom for VaD (Paul et al., 2005). Therefore, individuals who are
diagnosed with VaD may not typically seek initial assistance or evaluation from a
memory disorder clinic as their memory tends to be relatively intact. Thus, the
cases of AD compared to VaD in the present study may not be comparable to
epidemiological estimates as AD typically accounts for about 60-80% of
individuals diagnosed with dementia, followed by VaD with 20–25%, and then
mixed dementia 5–10% (Chen et al., 2009). These typical estimates were not seen
in the present study as 74% of individuals included in this study were diagnosed
with AD, only 7% were diagnosed with VaD, and 19% were diagnosed with
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mixed dementia (AD + VaD). The lack of VaD cases thereby might have
negatively impacted the results and contributed to the lack of significance and
rejection of Hypothesis 1. A larger group of VaD individuals might have led to
significant differences between diagnoses on M-WCST performance and thus
should be considered in future research.
Rather than a memory disorder clinic, individuals with VaD might initially
present to a hospital following a stroke or cerebrovascular accident as VaD itself
is defined as a decline in cognitive functioning resulting from ischemic or
hemorrhagic cerebrovascular disease (Paul et al., 2005). In fact, a recent study
conducted in China found that VaD was the most common type of dementia in
hospitalized patients (Wang et al., 2022). This study was a hospital populationbased cohort study meaning that data was collected from a Chinese national
database that covers 1531 tertiary hospitals within China. This large-scale study
provides support and an initial direction for future research on where exactly to
locate and recruit more patients with VaD.
Another reason for the lower number of VaD cases in the present study
might be attributable to the lack of referral for neuropsychological testing. In some
situations, medical providers might not believe that referral for
neuropsychological testing is absolutely necessary to make an accurate diagnosis.
In cases where an individual has a history of multiple strokes and clear cognitive
and functional deficits, a medical provider might not consider a referral for
neuropsychological testing where the focus is on differential diagnosis as it may
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already be obvious to the provider that the patient has VaD. Nevertheless, it is
imperative that future research incorporate a larger sample size for individuals
with VaD by perhaps looking at a hospital setting for recruitment of patients as
opposed to a memory disorder clinic.
Another limitation of the present study involves the lack of generalizability
to a diverse variety of populations, or low external validity. The majority of
individuals included in this study were Caucasian, as this tends to be the
demographic makeup of patients who present to the HFMDC. Therefore, a more
diverse sample of individuals should be gathered and utilized in future research
studies to help make the results more generalizable to the overall population.
One final limitation of the present study involves the inclusion criteria. This
study included all participants who were diagnosed with AD, VaD, and mixed
dementia (AD + VaD) who completed the M-WCST, TMT-B, and Color/Word
subtest without regulation of the degree of progression of each of the dementia
diagnoses. It would create a significant problem if there was a large number of
participants in more severe stages of dementia within the different diagnostic groups.
For example, when examining the present study, if there was a considerable number
of participants with severe dementia in the AD diagnostic group, this could result in
more individuals with AD performing poorly on the M-WCST. Thus, the degree of
dementia progression might pose as another reason for the lack of significance
observed between dementia diagnoses on M-WCST performance. A suggestion for
future research thereby involves screening each patient for the severity of their
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dementia before including them in the study. For example, as previously mentioned,
during the later stages of the disease many of the different dementias tend to
exhibit a similar and globally impaired cognitive profile (Howard, 2020).
Therefore, it is essential that future research determine a cut off or range for
inclusion of participants with dementia to enable greater accuracy in detecting
cognitive declines that are specific to particular diagnoses. One measure that
future researchers may utilize to determine a cut off for inclusion is the Montreal
Cognitive Assessment (MoCA), a brief cognitive screening measure. For example,
a MoCA score of <15 may indicate severe cognitive impairment and thus make it
difficult to differentiate between diagnoses. This concept should be looked into
further by future researchers.
Conclusion
The M-WCST is an important neuropsychological test as it assesses
perseveration, abstract reasoning, and mental flexibility (e.g., aspects of executive
functioning) using a smaller set of cards and modified rules resulting in less
patient frustration (Schretlen, 2010). The findings of this study provide support for
the continued clinical use of the M-WCST as a measure of executive functioning
as M-WCST scores were significantly correlated with performance on other
executive functioning measures. Furthermore, the M-WCST measures additional
aspects of executive functioning that the other two measures used in this study
(TMT-B and Color/Word) do not. For example, the M-WCST has been found to
measure aspects of complex problem solving with regards to the ability to switch
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cognitive strategies in response to changing environmental factors which can be
used to convey information regarding an individual’s judgment and decision
making (Kohli & Kaur, 2006). These considerations are especially useful when
working with an elderly or dementia population where there are concerns about an
individual’s ability to make financial, medical, and treatment decisions.
While M-WCST scores were not significantly different between
diagnostic groups as initially hypothesized, there were many potential reasons
explored above for this lack of significance. These reasons are in regards to
limitations of the present study (e.g., small VaD sample size, lack of exclusion of
severe dementia cases, etc.) rather than concerns with the M-WCST itself. Thus,
further research is indicated in order to determine the utility of the M-WCST in
differentiating between the diagnoses of VaD and AD. This study provided initial
support of the M-WCST with regards to its ability to detect a vascular component
to a dementia, by demonstrating the hypothesized trend of performance between
diagnostic groups, but future research is needed to determine statistical
significance and further direction of use. However, the findings from this study
did provide support for the use of TMT-B and the Color/Word subtest of the
Golden Stroop as measures that are capable of differentiating between AD, VaD,
and mixed dementia (AD + VaD). Therefore, it appears that TMT-B and
Color/Word may be more appropriate measures to use for differential diagnosis as
of right now awaiting further research on the M-WCST.
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Table 1.
Descriptive Statistics of Patient Demographic Information
Variable
AD
Gender
Female
Male
Race
Caucasian
African American
Asian
Native American
No Response
Ethnicity
Hispanic
Non-Hispanic
No Response
Age
65-69
70-79
80-89
90+
Level of Education
0 through 11th grade
High School
Some college
College graduate +
VaD
Gender
Female
Male
Race
Caucasian
African American
Asian
Native American
No Response
Ethnicity
Hispanic
Non-Hispanic
No Response
Age
65-69

77

N

Percent

129
69

65.2
34.8

171
19
5
1
2

86.4
9.6
2.5
0.5
1.0

10
186
2

5.1
93.9
1.0

13
76
105
4

6.6
38.3
53.1
2.0

16
74
48
60

8.1
37.4
24.2
30.3

12
7

63.2
36.8

18
1
0
0
0

94.7
5.3
0.0
0.0
0.0

1
18
0

5.3
94.7
0.0

0

0.0

70-79
80-89
90+
Level of Education
0 through 11th grade
High School
Some college
College graduate +
Mixed dementia
Gender
Female
Male
Race
Caucasian
African American
Asian
Native American
No Response
Ethnicity
Hispanic
Non-Hispanic
No Response
Age
65-69
70-79
80-89
90+
Level of Education
0 through 11th grade
High School
Some college
College graduate +
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5
13
1

26.3
68.4
5.3

3
5
9
2

15.8
26.3
47.4
10.6

30
21

58.8
41.2

50
1
0
0
0

98.0
2.0
0.0
0.0
0.0

0
51
0

0.0
100.0
0.0

0
19
26
6

0.0
37.3
50.9
11.8

5
19
13
14

9.8
37.3
25.5
27.5

Figure 1.
The Effect of Dementia Diagnosis on M-WCST Performance
30

M-WCST Performance

25
20
15
10
5
0
Categories completed

Total errors

Perseverative errors

Dementia Diagnosis
VaD

Mixed (AD+VaD)

AD

Note. Mean scores are shown for M-WCST variables within the predicted trend of
performance noted in Hypothesis 1.

79

Table 2.
M-WCST Performance Variables Correlated with Other Executive Functioning Measures
Variable
M
SD
rs
M-WCST Number of Categories Correct

2.24

1.38

Stroop Color/Word

14.57

8.64

.272**

Trail Making Test - B

241.53

73.34

-.334**

26.04
14.57
241.53
12.74
14.57
241.53

8.76
8.64
73.34
9.13
8.64
73.34

M-WCST Total Number of Errors
Stroop Color/Word
Trail Making Test - B
M-WCST Number of Perseverative Errors
Stroop Color/Word
Trail Making Test - B
Note. ** p < .001
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-.294**
.325**
-.286**
.310**

